Drug Trial Radar · NCT05135546
Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial
Last checked: Nov 20, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
4
Actual
Start
Dec 27, 2021
Primary completion
Feb 1, 2023
Study completion May 31, 2023
Sponsor
- Lead sponsor
- Supergene, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Russian Academy of Medical Sciences
- First posted
- Nov 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objective: to evaluate the tolerability, safety and efficacy of inhaled usage of the Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) vs placebo in patients with COVID-19.
Conditions
- COVID-19
Interventions
Recombinant nonimmunogenic staphylokinaseDrug
15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin®
PlaceboDrug
6 ml of 0.9% solution of NaCl for inhalation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients discharged from the hospital with clinical status according to the WHO Ordinal Scale For Clinical Improvement - 3 points or lessTime frame: 28 days post randomization
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
City Clinical Hospital No.52
Moscow, Russia
N.V. Sklifosovsky Research Institute of Emergency Medicine
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.